25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Patent number: 8933039Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: GrantFiled: June 15, 2010Date of Patent: January 13, 2015Assignees: NPS Pharmaceuticals, Inc., 1149336 Ontario Inc.Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
-
Publication number: 20150011474Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6X7EID X11LPNL X16X17X18QW X21AFIX23X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatments.Type: ApplicationFiled: February 19, 2013Publication date: January 8, 2015Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
-
Publication number: 20150011017Abstract: The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.Type: ApplicationFiled: September 5, 2014Publication date: January 8, 2015Applicant: BRAHMS GmbHInventors: ANDREAS BERGMANN, Joachim Struck
-
Publication number: 20150011467Abstract: Compounds of the invention are novel peptide analogues of oxyntomodulin (oxm) in which one or more amino acids of the oxm sequence have been changed. Changing amino acids 15-24 of oxm to either amino acids 968-977 of the ?-latrotoxin peptide (and variations thereof) or amino acids 15-24 of exendin-4 (and variations thereof), or combinations of sequences from these sources, and/or changing amino acids 27-33 of oxm to amino acids 27-33 of exendin-4, and/or the addition of amino acids to the C-terminus of the peptide, results in a series of analogues of oxm that demonstrate the oxm like activity of reducing food intake, and with certain embodiments a greater ability to decrease food intake.Type: ApplicationFiled: April 10, 2014Publication date: January 8, 2015Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Stephen Robert Bloom, Mohammad Ali Ghatei
-
Patent number: 8927225Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.Type: GrantFiled: September 8, 2009Date of Patent: January 6, 2015Assignee: The University of Hong KongInventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
-
Patent number: 8927489Abstract: The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.Type: GrantFiled: June 2, 2006Date of Patent: January 6, 2015Assignee: Cebix IncorporatedInventors: John Wahren, Anders Carlsson
-
Patent number: 8927488Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.Type: GrantFiled: May 17, 2011Date of Patent: January 6, 2015Assignee: Cebix, Inc.Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
-
Publication number: 20150004192Abstract: The invention provides a recombinant polypeptide X-Y for enhancing cell transduction efficiency of a target agent, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Also provided is a method for enhancing cell transduction efficiency of a target agent, comprising conjugating/attaching said target agent with a recombinant polypeptide X-Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain. Further provided is a pharmaceutical composition comprising a therapeutic agent, wherein said therapeutic agent is modified by conjugating/attaching with a recombinant polypeptide X-Y, wherein X is a cell penetrating peptide DPV3, and Y is an Hsp40-J domain.Type: ApplicationFiled: June 30, 2014Publication date: January 1, 2015Inventors: CHIN-KAI CHUANG, YU-HSYU SU, TZUYIN LIN
-
Publication number: 20150004157Abstract: The present invention relates to a therapeutic comprising an osteopontin isoform a (“OPNa”) inhibitor where the OPNa inhibitor blocks activity of extracellular OPNa exon 4. The OPNa inhibitor is selected from the group consisting of (i) an exon-4 specific antibody or binding portion thereof; (ii) a peptide mimic of OPNa exon 4 or a fragment thereof; (iii) a nucleic acid aptamer that specifically binds to OPNa exon 4 or a fragment thereof; and (iv) a peptide inhibitor that binds to OPNa exon 4 or a fragment thereof. The present invention also relates to methods of inhibiting tumor growth and/or metastasis in a subject, treating a subject with chemotherapeutic resistance, and methods of increasing tumor cell sensitivity to a cancer therapeutic by administering an OPNa inhibitor according to the present invention.Type: ApplicationFiled: February 13, 2013Publication date: January 1, 2015Applicant: NEW YORK UNIVERSITYInventors: Harvey I. Pass, Jessica S. Donington, Chandra M. Goparaju
-
Publication number: 20150004185Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: ApplicationFiled: April 29, 2014Publication date: January 1, 2015Applicant: University of SaskatchewanInventors: Kristen Marciniuk, Ryan Taschuk, Scott Napper, Andrew Potter, Neil Cashman
-
Publication number: 20150004137Abstract: The present invention relates to heterogeneous or artificially created forms of plant defensins, and to uses of such heterogenous or artificially created defensins including methods for preventing or treating proliferative diseases. Compositions for use as animal and human medicaments are also provided. The present invention also relates to associated methods, uses, systems and kits.Type: ApplicationFiled: October 19, 2012Publication date: January 1, 2015Applicant: BALMORAL AUSTRALIA PTY LTDInventors: Mark Darren Hulett, Ivan Ka Ho Poon
-
Publication number: 20150004189Abstract: The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.Type: ApplicationFiled: February 7, 2013Publication date: January 1, 2015Inventors: Alessandro Sette, Carla Oseroff, Howard Grey, Bjoern Peters
-
Patent number: 8921516Abstract: The present invention discloses compositions for applications that mimic fibronectin coated surfaces. Advantageously, such compositions provide an animal free (xeno-free, and human-component-free), synthetic, chemically defined surface that mimics at least one of the functionalities of fibronectin.Type: GrantFiled: December 2, 2011Date of Patent: December 30, 2014Assignee: Corning IncorporatedInventor: Deepa Saxena
-
Publication number: 20140378382Abstract: Described are polypeptide analogs of parathyroid hormone (PTH) that include at least two non-adjacent ?-amino acid residues in place of a naturally occurring ?-amino acid residues. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.Type: ApplicationFiled: June 23, 2014Publication date: December 25, 2014Applicant: Massachusetts General HospitalInventors: Samuel H. Gellman, Ross W. Cheloha, Thomas J. Gardella
-
Publication number: 20140378653Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.Type: ApplicationFiled: January 31, 2013Publication date: December 25, 2014Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
-
Publication number: 20140377542Abstract: A plate with titanium dioxide on its surface, as well as its manufacturing process and uses thereof are provided. The plate comprises (A) a substrate; (B) a polydimethylsiloxane (PDMS) layer on at least one surface of the substrate; and (C) one or more aggregations of titanium dioxide particles on the polydimethylsiloxane layer. The plate is useful in the purification of phosphopeptides.Type: ApplicationFiled: September 12, 2013Publication date: December 25, 2014Inventors: Chao-Jung Chen, Yu-Ching Liu
-
Publication number: 20140378384Abstract: A series of polypeptides presenting high integrin affinity and bonding capacity is provided. Three polypeptides among said series can be adopted in prevention and treatment of rheumatoid arthritis. Said three polypeptides are: polypeptide I: Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro (SEQ ID NO. 1) (two pairs of disulfide bonds contained in the sequence are pairing in the pattern of 1-4 and 2-3); Polypeptide II: Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO. 2); and polypeptide III: mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO. 3). These polypeptides can be adopted in treatment of rheumatoid arthritis.Type: ApplicationFiled: December 25, 2012Publication date: December 25, 2014Inventor: HANMEI XU
-
Publication number: 20140377178Abstract: The present invention relates to a method of labelling biological molecules with 18F, via attachment to fluorine to a macrocyclic metal complex of a non-radioactive metal, where the metal complex is conjugated to the biological molecule. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.Type: ApplicationFiled: January 22, 2013Publication date: December 25, 2014Applicants: UNIVERSITY OF SOUTHAMPTON, GE HEALTHCARE LIMITEDInventors: Rajiv Bhalla, Sajinder Kaur Luthra, Gill Reid, I, William Levason
-
Publication number: 20140377179Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.Type: ApplicationFiled: March 20, 2014Publication date: December 25, 2014Applicant: The United States of America,as represented by the Secretary, Department of Health & Human ServicesInventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza
-
Patent number: 8916517Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.Type: GrantFiled: November 2, 2010Date of Patent: December 23, 2014Assignee: The Administrators of the Tulane Educational FundInventors: David H. Coy, Jerome L. Maderdrut, Min Li
-
Patent number: 8916680Abstract: Methods are described for measuring the amount of a kisspeptin-54-derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying a kisspeptin-54 derived peptides in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.Type: GrantFiled: November 20, 2012Date of Patent: December 23, 2014Assignee: Quest Diagnostics Investments, Inc.Inventors: Cory E. Bystrom, Richard E Reitz
-
Patent number: 8916689Abstract: The present invention relates to site-specific labeling of antibodies or fragments thereof with one or more reporter group(s) in a way that does not affect antigen binding. The method for labeling antibodies and/or fragments thereof, comprises the following steps a) providing an IgG binding protein, which comprises ?-helix structures, with a photoactivatable group and at least one label; b) forming a mixture of said IgG binding protein and the antibodies and/or fragments to be labeled; and c) UV illuminating said mixture for site-specific labeling of said antibodies and/or fragments thereof. The IgG binding protein is preferably the Z domain of Protein A.Type: GrantFiled: September 5, 2011Date of Patent: December 23, 2014Assignee: GE Health Bio-Sciences ABInventors: Sophia Hober, Amelie Eriksson Karlstrom, Anna Konrad
-
Publication number: 20140371148Abstract: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.Type: ApplicationFiled: June 18, 2014Publication date: December 18, 2014Inventors: Soumitra S. GHOSH, Josue ALFARO-LOPEZ, Lawrence J. D'Souza, Odile Esther LEVY, Qing LIN, Christopher J. SOARES
-
Publication number: 20140370023Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.Type: ApplicationFiled: May 27, 2014Publication date: December 18, 2014Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
-
Publication number: 20140371146Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: June 19, 2014Publication date: December 18, 2014Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Publication number: 20140370042Abstract: Internally cross-linked peptides useful for interfering with Respiratory Syncytial Virus (RSV) infection is based on RSV-F protein. These peptides are capable of reducing infection in cellular and animal models.Type: ApplicationFiled: December 31, 2012Publication date: December 18, 2014Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Loren D. WALENSKY, Gregory H BIRD
-
Publication number: 20140369930Abstract: The present invention relates to a pharmaceutical composition comprising a cyclotide for use in immune suppression as well as to a method for immune suppression comprising the step of administering an effective amount of a pharmaceutical composition comprising such a cyclotide to a subject in need thereof. The present invention also relates to a pharmaceutical composition comprising a cyclotide for use in treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation. Likewise, the present invention also relates to a method for treating or preventing a disorder selected from the group consisting of (i) an autoimmune disorder; (ii) a hypersensitivity disorder; and (iii) a lymphocyte-mediated inflammation.Type: ApplicationFiled: December 21, 2012Publication date: December 18, 2014Inventors: Christian Werner Gruber, Carsten Gruendemann
-
Patent number: 8912310Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.Type: GrantFiled: May 29, 2013Date of Patent: December 16, 2014Assignee: Duke UniversityInventors: Ashutosh Chilkoti, Felipe Garcia Quiroz
-
Patent number: 8912139Abstract: Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.Type: GrantFiled: March 31, 2014Date of Patent: December 16, 2014Assignee: The Board of Trustees of the University of IllinoisInventors: Yulia A. Komarova, Uzma Saqib, Stephen M. Vogel, Asrar B. Malik
-
Publication number: 20140363462Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.Type: ApplicationFiled: July 31, 2014Publication date: December 11, 2014Inventors: Maria ARICÒ, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA
-
Publication number: 20140363375Abstract: Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.Type: ApplicationFiled: March 13, 2014Publication date: December 11, 2014Applicant: Promega CorporationInventors: Andrew S. Dixon, Lance Encell, Mary Hall, Keith Wood, Monika Wood, Marie Schwinn, Brock F. Binkowski, Hicham Zegzouti, Nidhi Nath, Subhanjan Mondal, Said Goueli, Poncho Meisenheimer, Thomas Kirkland, James Unch, Dileep K. Pulukkunat, Matthew Robers, Melanie Dart, Thomas Machleidt
-
Patent number: 8906844Abstract: The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.Type: GrantFiled: August 1, 2008Date of Patent: December 9, 2014Assignee: Biogen Idec Hemophilia Inc.Inventors: Adam R. Mezo, Kevin A. McDonnell
-
Patent number: 8907054Abstract: Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to radial spoke protein 3 (RSP3) or absent, small, homeotic discs 2-like protein (Ash2L) and that bind to Dumpy-30 protein (Dpy-30).Type: GrantFiled: August 8, 2012Date of Patent: December 9, 2014Assignee: Marquette UniversityInventors: Pinfen Yang, Priyanka Sivadas
-
Patent number: 8906845Abstract: The disclosure provides peptide compounds that regulate the complement system and methods of using these compounds. Specifically the disclosure provides an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The peptide compounds disclosed include peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and/or substitutions, deletions and/or substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The disclosure further provides pharmaceutical compositions comprising therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.Type: GrantFiled: July 21, 2011Date of Patent: December 9, 2014Assignee: Eastern Virginia Medical SchoolInventors: Neel K. Krishna, Kenji M. Cunnion
-
Publication number: 20140356320Abstract: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.Type: ApplicationFiled: July 23, 2012Publication date: December 4, 2014Applicant: Universität ZürichInventors: Ilijas Jelcic, Roland Martin, Sven Schippling, Mireia Sospedra, Sara Yousef
-
Publication number: 20140357512Abstract: The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker peptides, which are acetylated, for multiple myeloma. Alternatively, the biomarkers are drug specific, HDAC6 biomarker peptides, which are acetylated or unacetylated, for multiple myeloma. The invention also relates to a kit comprising a detection agent and instructions for identifying a biomarker peptide of the invention. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.Type: ApplicationFiled: June 3, 2014Publication date: December 4, 2014Applicant: ACETYLON PHARMACEUTICALS, INC.Inventors: Min Yang, Simon S. Jones
-
Publication number: 20140357543Abstract: An object of the present invention is to provide proteinaceous protease inhibitors with moderate inhibitory activity.Type: ApplicationFiled: October 5, 2012Publication date: December 4, 2014Inventors: Miki Kusano, Fusamitsu Yanagihara
-
Publication number: 20140357577Abstract: The present invention concerns an inhibitor of Human Immunodeficiency Virus (HIV) fusion with, or HIV entry in, a host cell comprising at least 24, but preferably 26, contiguous amino acids; the invention also relates to a pharmaceutical composition comprising said amino acids.Type: ApplicationFiled: December 18, 2012Publication date: December 4, 2014Inventors: Bruce Albert Malcolm, Johannes Wilhelmus J. Thuring, Christophe Francis Robert Nestor Buyck, Wim Bert Griet Schepens, Maria Aldegonda Jacoba Kriek, Wilhelmus Martinus Maria Schaaper, Jelle Wouter Slootstra, Peter Timmerman
-
Publication number: 20140357840Abstract: The present invention relates to a method for producing a transfer factor. The method comprises the following steps: freezing and thawing of peripheral-blood leukocytes, dialysis, tangential ultrafiltration, identification and quantification using high-resolution, molecular-exclusion liquid chromatography, and in vitro biological validation. The resulting product is suitable for medical use.Type: ApplicationFiled: December 17, 2012Publication date: December 4, 2014Inventors: Sergio Estrada-Parra, Iris Citlati Elvira Estrada-Garcia, Sonia Mayra Pérez-Tapia
-
Publication number: 20140356409Abstract: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.Type: ApplicationFiled: December 21, 2012Publication date: December 4, 2014Inventor: Patrick M. Schlievert
-
Publication number: 20140357520Abstract: The present invention relates to novel peptides that may be used in whole or in combination for the detection of Mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from M. tuberculosis or vaccination using an epitope specific inoculation. More particularly, the present invention provides a means to distinguish early, active, and latent M. tuberculosis infection. More particularly, the present invention describes an immunological diagnostic mechanism for the detection of M. tuberculosis infection.Type: ApplicationFiled: February 7, 2013Publication date: December 4, 2014Inventor: Kimberly Luke
-
Publication number: 20140356344Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.Type: ApplicationFiled: August 20, 2014Publication date: December 4, 2014Applicant: BioAtla LLCInventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
-
Patent number: 8900551Abstract: The present invention relates to a peptide that passes through a blood-brain barrier and binds specifically to apoptotic cells in neurodegenerative brain disease-affected sites, and uses thereof. Therefore, the peptide of the present invention can be used for detecting and imaging apoptotic cells in neurodegenerative brain disease-affected sites, and for targeted drug delivery and theranosis of neurodegenerative brain diseases.Type: GrantFiled: May 11, 2012Date of Patent: December 2, 2014Assignee: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Byung-Heon Lee, In-San Kim, Jae-Sung Bae, Hee Kyoung Jin, Hyung Soo Han
-
Patent number: 8900826Abstract: A chemoenzymatic method for the preparation of a homogeneous glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of GlcNAc-protein and GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of a catalyst comprising endoglycosidase (ENGase), to transfer the oligosaccharide moiety to the acceptor and yield the homogeneous glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of glycoprotein or glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody including a heterogeneous sugar chain, are also described. The disclosed methodology enables glycoprotein drugs to be modified for prolonged half-life in vivo, reduced immunogenicity, and enhanced in vivo activity, and for targeting and drug delivery.Type: GrantFiled: January 9, 2013Date of Patent: December 2, 2014Assignee: University of Maryland, BaltimoreInventor: Lai-Xi Wang
-
Patent number: 8901073Abstract: Peptide analogs of peptide YY (PYY), compositions comprising them, and methods of using those analogs or compositions for the treatment and prevention of metabolic disorders, for example disorders of energy metabolism such as diabetes and obesity, and for reduction in appetite, reduction in food intake or reduction of calorie intake in a subject, are provided herein.Type: GrantFiled: January 27, 2012Date of Patent: December 2, 2014Assignee: Imperial Innovations LimitedInventor: Stephen Robert Bloom
-
Publication number: 20140350218Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: April 15, 2014Publication date: November 27, 2014Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: MAREN WATKINS, BALDOMERO M. OLIVERA, DAVID R. HILLYARD, J. MICHAEL MCINTOSH
-
Publication number: 20140348862Abstract: The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.Type: ApplicationFiled: July 18, 2013Publication date: November 27, 2014Applicant: Academisch Ziekenhuis Leiden h.o.d.n. LUMCInventors: Jan Kessler, Marieke Griffioen, Cornelis Johannes Maria Melief, Jan Wouter Drijfhout
-
Publication number: 20140348902Abstract: Provided are TCL1 peptides that bind to MHC I (HLA-A2) on tumor cells or other antigen-presenting cells and are recognized by T-cell receptors on T cells. The TCL1 peptides may be therapeutically used to treat a cancer, such as a B cell malignancy, leukemia, or lymphoma. Methods for expanding a population of T cells that target TCL1 are also provided.Type: ApplicationFiled: November 19, 2012Publication date: November 27, 2014Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Sattva S. Neelapu, Jinsheng Weng
-
Publication number: 20140348864Abstract: A procine circovirus type-2 (PCV2) immunogenic composition includes an antigenic peptide. The antigenic peptide is a non-arginine-rich peptide of a PCV2 open reading frame 2 (ORF2) and/or a recombinant fusion protein having the non-arginine-rich peptide of the PCV2 ORF2, a PE peptide, and a KDEL signal peptide. The number of arginines of the non-arginine-rich peptide of the PCV2 ORF2 is not greater than half of the number of arginines of the arginine-rich domain of the N terminal of the PCV2 ORF2.Type: ApplicationFiled: December 5, 2012Publication date: November 27, 2014Inventors: Tsun-Yung Kuo, Hsu-Chung Gabriel Chen, Shu-Hsiang Yang, Yu-San Chen
-
Publication number: 20140348861Abstract: Synthetic peptides and peptide copolymers for amelioration of autoimmune neurological syndrome, inflammatory and/or demyelinating conditions such as encephalomyletis are provided herein. The synthetic peptides and peptide copolymers as disclosed are obtained by substitution of at least one alpha amino acid by beta amino acid and/or ?3-homo amino acid.Type: ApplicationFiled: May 3, 2012Publication date: November 27, 2014Applicant: NATIONAL INSTITUTE OF IMMUNOLOGYInventors: Avadhesha Surolia, Ravi Kant Gautam, Vishnu Kumar Dwivedi, Sarika Gupta